URO Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd. (TSX VENTURE: URO) today announces that it has commenced a pilot sales and marketing program with Cardinal Health for its uroNIRS 2000, an innovative technology for the non-invasive diagnosis of bladder conditions. The 90-day pilot program will be used to by Urodynamix and Cardinal Health to evaluate the viability of adding the uroNIRS 2000 to Cardinal Health's catalogue of offerings to the urology market.

The uroNIRS 2000 provides a real-time, non-invasive evaluation of the bladder function during voiding to aid in the diagnosis of bladder outlet obstruction. The product is approved for sale in the U.S.

About Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd. is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contacts: Urodynamix Technologies Ltd. Jonathan Jackson CA Chief Financial Officer (604) 613-6116 jjackson@urodynamix.com www.urodynamix.com